PMID- 36533600
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230107
IS  - 2532-179X (Electronic)
IS  - 1124-0490 (Print)
IS  - 1124-0490 (Linking)
VI  - 39
IP  - 4
DP  - 2022 Dec 19
TI  - Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic 
      interstitial pneumonias.
PG  - e2022038
LID - 10.36141/svdld.v39i4.13682 [doi]
LID - e2022038
AB  - BACKGROUND AND AIM: Acute exacerbation (AE) of idiopathic pulmonary fibrosis 
      (IPF) is a fatal condition with no established treatment. Intravenous 
      immunoglobulin (IVIG) is a unique therapy with both anti-inflammatory and 
      anti-infective effects. Therefore, we hypothesized that IVIG may have a positive 
      effect on AE of interstitial pneumonia. This study aimed to determine the effect 
      of IVIG in patients with AE of fibrotic idiopathic interstitial pneumonias 
      (IIPs), including IPF. METHODS: We retrospectively analyzed consecutive patients 
      who were diagnosed with AE of fibrotic IIPs and treated with pulse corticosteroid 
      therapy (methylprednisolone 500-1000 mg/day for 3 days) between April 2018 and 
      May 2021 at Kagawa Rosai Hospital and KKR Takamatsu Hospital. RESULTS: This study 
      included 52 patients with AE of fibrotic IIPs (IPF,41; fibrotic IIPs other than 
      IPF,11). Thirteen patients received IVIG (5 g/day for 3-5 days) concurrently with 
      pulse corticosteroid therapy. The remaining 39 patients were assigned to the 
      control group. The survival rate on day 90 was significantly higher in the IVIG 
      group than that in the control group (76.9% vs. 38.5%, p = 0.02). IVIG 
      administration (odds ratio [OR], 0.11; 95% confidence interval [CI], 0.02-0.69; p 
      = 0.02) and C- reactive protein (OR, 1.19; 95% CI, 1.06-1.33, p < 0.01) were 
      independently associated with 90-day mortality. CONCLUSIONS: The results indicate 
      that administration of IVIG may improve the survival of patients with AE of 
      fibrotic IIPs. We are now conducting a prospective study to confirm the effect of 
      IVIG on AE of IPF since May 2022 (jRCT1061220010).
FAU - Higo, Hisao
AU  - Higo H
AD  - Okayama University Hospital. hhigo@okayama-u.ac.jp.
FAU - Ichikawa, Hirohisa
AU  - Ichikawa H
AD  - KKR Takamatsu Hospital. ichikawa@kkr-ta-hp.gr.jp.
FAU - Nakamura, Naoki
AU  - Nakamura N
AD  - KKR Takamatsu Hospital. n.naoki.0126@gmail.com.
FAU - Fujii, Masanori
AU  - Fujii M
AD  - Okayama University Hospital. feynman8@okayama-u.ac.jp.
FAU - Matsuoka, Katsuhiro
AU  - Matsuoka K
AD  - KKR Takamatsu Hospital. me421077@s.okayama-u.ac.jp.
FAU - Seki, Shoko
AU  - Seki S
AD  - KKR Takamatsu Hospital. seki@kkr-ta-hp.gr.jp.
FAU - Wada, Takamasa
AU  - Wada T
AD  - Kagawa Rosai Hospital. wadatakamasa531881@gmail.com.
FAU - Suzaki, Noriyuki
AU  - Suzaki N
AD  - Kagawa Rosai Hospital. n-suzaki@kagawah.johas.go.jp.
FAU - Nagata, Takuya
AU  - Nagata T
AD  - Kagawa Rosai Hospital. tnagata@kagawah.johas.go.jp.
FAU - Arakawa, Yukako
AU  - Arakawa Y
AD  - KKR Takamatsu Hospital. arakawa@kkr-ta-hp.gr.jp.
FAU - Mori, Yoshihiro
AU  - Mori Y
AD  - KKR Takamatsu Hospital. mori@kkr-ta-hp.gr.jp.
FAU - Marukawa, Masaomi
AU  - Marukawa M
AD  - Kagawa Rosai Hospital. masaomi-marukawa@shigei.or.jp.
FAU - Kiura, Katsuyuki
AU  - Kiura K
AD  - Okayama University Hospital. kkiura@md.okayama-u.ac.jp.
FAU - Maeda, Yoshinobu
AU  - Maeda Y
AD  - Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical 
      Sciences. yosmaeda@md.okayama-u.ac.jp.
FAU - Miyahara, Nobuaki
AU  - Miyahara N
AD  - Okayama University Graduate School of Health Sciences. 
      miyahara@md.okayama-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20221219
PL  - Italy
TA  - Sarcoidosis Vasc Diffuse Lung Dis
JT  - Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
JID - 9610928
PMC - PMC9798342
COIS- The authors have no conflicts of interest to declare.
EDAT- 2022/12/20 06:00
MHDA- 2022/12/20 06:01
PMCR- 2022/01/01
CRDT- 2022/12/19 06:03
PHST- 2022/09/11 00:00 [received]
PHST- 2022/11/12 00:00 [accepted]
PHST- 2022/12/19 06:03 [entrez]
PHST- 2022/12/20 06:00 [pubmed]
PHST- 2022/12/20 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - SVDLD-39-38 [pii]
AID - 10.36141/svdld.v39i4.13682 [doi]
PST - epublish
SO  - Sarcoidosis Vasc Diffuse Lung Dis. 2022 Dec 19;39(4):e2022038. doi: 
      10.36141/svdld.v39i4.13682.